Jason J Luke
Overview
Explore the profile of Jason J Luke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
8311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luke J, Pinato D, Juric D, LoRusso P, Hosein P, Desai A, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39979069
E7766 is a novel stimulator of interferon genes (STING) agonist, capable of potent activation of immune cells and generating strong antitumor response in preclinical murine tumor models. Here we present...
2.
Yoon C, Ross M, Gastman B, Luke J, Ascierto P, Long G, et al.
Ann Surg Oncol
. 2025 Feb;
32(4):2756-2764.
PMID: 39893343
Background: Previous results from the KEYNOTE-716 trial demonstrated significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with adjuvant pembrolizumab versus placebo in patients with resected stage IIB or...
3.
Luke J, Sweis R, Hecht J, Schneider R, Stein M, Golan T, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39846804
Background: We evaluated the non-cyclic dinucleotide stimulator of interferon genes agonist MK-2118 ± pembrolizumab in patients with advanced solid tumors or lymphomas. Methods: This first-in-human study (NCT03249792) enrolled patients with...
4.
5.
Lehrich B, Monga S, Delgado E, Lehrich B, Delgado E, Yasaka T, et al.
Res Sq
. 2024 Dec;
PMID: 39711542
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in (encoding for β-catenin), , or ,...
6.
Luke J, Gelmon K, Siu L, Moreno V, Desai J, Gomez-Roca C, et al.
Clin Cancer Res
. 2024 Dec;
PMID: 39670852
Purpose: To evaluate linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies. Patients And Methods: In this...
7.
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar D, Morrison R, Dzutsev A, Karunamurthy A, Chauvin J, Amatore F, et al.
Cancer Cell
. 2024 Nov;
42(11):1898-1918.e12.
PMID: 39486411
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma....
8.
Lynch C, Korpics M, Katipally R, Bestvina C, Pitroda S, Patel J, et al.
Eur J Cancer
. 2024 Aug;
209:114264.
PMID: 39106643
Background: Stereotactic body radiotherapy (SBRT) is safe and effective for treatment of extracranial metastatic disease, but its safety when combined with immune checkpoint inhibitors (ICI) has not yet been comprehensively...
9.
10.
Mowery Y, Luke J
Clin Cancer Res
. 2024 Jul;
30(18):3965-3967.
PMID: 39007757
Neutrophil extracellular trap (NET)osis via lytic neutrophil death or neutrophil activation is associated with standard cancer therapies, notably including radiotherapy; is immunosuppressive; and may enhance metastasis and treatment resistance. This...